On the other hand, it was argued that the excess lymphocyte infiltration in breast cancers involving BRCA1 mutations is simply an exaggeration of a phenotypic feature that has no bearing on disease progression [38]. This evidence concerns the gene BRCA1 and breast carcinoma.